Immediate Impact

1 by Nobel laureates 3 from Science/Nature 52 standout
Sub-graph 1 of 25

Citing Papers

Lorlatinib Versus Crizotinib in Patients With Advanced ALK -Positive Non–Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study
2024 Standout
Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer
2023 Standout
1 intermediate paper

Works of J Gordon being referenced

Symptom and Quality of Life Improvement in LUX-Lung 8, an Open-Label Phase III Study of Second-Line Afatinib Versus Erlotinib in Patients With Advanced Squamous Cell Carcinoma of the Lung After First-Line Platinum-Based Chemotherapy
2017

Author Peers

Author Last Decade Papers Cites
J Gordon 288 245 189 244 46 950
M Gábor 125 149 74 98 52 743
Ivan Bašić 19 106 154 88 42 970
Ping Liu 23 31 156 67 31 987
Mehrdad Gholami 25 53 104 22 66 856
Yoshimi Ohno 156 129 156 27 60 756
Avneesh Gupta 32 215 157 15 65 1.0k
G. Rai 15 81 7 190 41 1.1k
Kuldeep Sharma 12 76 20 41 68 830
Ming Zeng 13 119 48 167 68 1.1k
Rajesh Kumar 6 75 34 99 62 983

All Works

Loading papers...

Rankless by CCL
2026